Research projects

Advancing Research, Transforming Lives

At FH Europe Foundation, research is never just about data. It is about people, families, and lives that can be changed through earlier diagnosis, better care, and stronger prevention.

Across Europe, millions of people live with inherited lipid disorders such as familial hypercholesterolaemia (FH), homozygous FH (HoFH), elevated Lp(a), and familial chylomicronaemia syndrome (FCS). Too many remain undiagnosed until they experience serious cardiovascular events that could have been prevented.

This is why FH Europe Foundation is actively involved in several European and international research projects dedicated to improving the detection, diagnosis, management, and long-term care of inherited lipid disorders.

By working alongside clinicians, researchers, policymakers, and patient communities, we help ensure that research reflects real patient needs and leads to real-world impact. From advancing screening strategies and digital health solutions to strengthening prevention pathways and equitable access to care, our contribution is grounded in one core principle: patients must remain at the centre of innovation.

We believe research must do more than generate knowledge. It must create change.

Every project we support is driven by the same goal: to prevent avoidable suffering, reduce inequalities in care, and give every person affected by inherited lipid disorders the opportunity for earlier diagnosis, better treatment, and a healthier future.

Because behind every statistic is a person waiting to be seen, heard, diagnosed, and protected.
PERFECTO (“Preventing the Preventable”) is a pan‑European initiative focused on paediatric screening for Familial Hypercholesterolaemia (FH), the most common inherited cause of high cholesterol. By targeting early detection in children, the project aims to reduce premature heart disease and inform EU-wide policy, backed by five integrated work streams spanning advocacy, communication, health equity, scientific evidence, and management. 
Co-funded by the European Union
https://perfecto-fh.eu/
FH-EARLY is a multi-national initiative aiming to co-develop with patients, three core solutions to improve the early diagnosis, risk stratification, and co-management of FH: a chip array, a clinically tested biomarker assay and an integrative AI-powered health profiling tool. 
Funded by the European Union
https://fh-early.eu/
PerMed FH aims to bring personalised medicine protocol integrating all dimensions, from clinical diagnosis to molecular diagnosis to functional genomics. We will also provide evidence that functional assays, apart from being essential for determining variant pathogenicity, can be used to tailor the therapeutic strategy for FH patients.
https://permedfh.eu/